Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall pleased to include Efficib in portfolio

Almirall pleased to include Efficib in portfolio

6th May 2009

Almirall is pleased to incorporate Efficib into its portfolio, it has asserted.

The company has launched the drug ? which is a combination of sitagliptin and metformin in a single tablet ? to treat type 2 diabetes in Spain as part of a co-marketing agreement signed with Merck Sharp and Dohme.

It works by targeting insulin resistance, excess of hepatic glucose production and lack of insulin created by pancreatic beta cells.

The improvement of compliance by use of two antidiabetic agents to improve glycemic control is one of the advantages of the treatment.

Enrique Dominguez is Almirall’s general manager in Spain and remarked the firm is pleased to have the remedy in its range.

“This new product will greatly benefit many type 2 diabetes patients by enabling them to control their glucose levels more efficiently and easily,” he said.

Earlier this week, the pharmaceutical company announced it would be responsible for the commercialisation of linaclotide in all EU countries, as well as Russia, Switzerland, Norway and Turkey as part of a licensing agreement with Ironwood.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.